HIGHLIGHTS
- Five-year European supply agreement executed with Centro Fertilita Assistita (CFA Italia), one of Italy’s largest private IVF groups based in Naples, Italy.
- Minimum purchase commitments of 3,000 cartridges in the first 24 months, followed by 1,500 cartridges annually thereafter.
- Minimum contract value of €525,000 (~A$925,000), based on 7,500 contracted cartridges at €70 per cartridge.
- CFA Italia has placed an initial purchase order for 500 Felix™ cartridges (A$62,500) ahead of CE Mark approval and any contractual obligation, validating strong clinical demand under Memphasys’ direct commercialisation model.
- Revenue recognised in the current quarter and cash receipt expected next quarter.
- Order received following on-site engagement, training and clinical onboarding with CFA Italia, reinforcing the effectiveness of Memphasys’ company-led commercial strategy.
- CFA also has established commercial relationships with numerous IVF clinics across Italy and will commence engaging these clinics to promote and sell Felix™.
- First European commercial agreement, expanding Memphasys’ contracted footprint alongside agreements in Japan, India and the Middle East. • Early demand from CFA Italia supports potential to exceed minimum contracted volumes, with further European orders expected.
Memphasys Limited (ASX: MEM) (“Memphasys” or “the Company”) is pleased to announce it has executed a long-term, five-year commercial supply agreement with Centro Fertilita Assistita (CFA) Italia, an established IVF group based in Naples, Italy.
Under the Agreement, CFA Italia will purchase and deploy the Felix™ automated sperm isolation system within its IVF clinics and broader distribution network across Italy. Key commercial terms include:
- 3,000 Felix™ cartridges to be purchased across the first 24 months;
- 1,500 cartridges annually from Years 3–5, equating to a minimum contract volume of 7,500 cartridges;
- Cartridge pricing of €70 per cartridge.
Following targeted in-market clinical and commercial engagement, the Company has secured an initial commercial order for 500 Felix™ cartridges (A$62,500), with revenue to be recognised in the current quarter and cash receipt expected in the following quarter. This early order, received ahead of CE Mark activation, reflects strong clinical interest generated through Memphasys’ direct engagement model and provides early validation of the Felix™ System and the Company’s direct commercialisation strategy.
Strategic milestone in European market expansion
This Agreement represents Memphasys’ first commercial contract in mainland Europe, marking a key milestone in the Company’s commercial rollout. The receipt of an initial commercial order following handson commercial and clinical engagement underscores the effectiveness of Memphasys’ direct commercialisation strategy and highlights growing demand for the Felix™ System ahead of CE Mark approval.
In addition, CFA has established relationships with a broad network of IVF clinics across Italy, representing a significant incremental commercial opportunity for Felix™. Italy is a major centre for assisted reproductive technology, with tens of thousands of IVF cycles performed annually, underscoring the large and growing demand for fertility solutions in the region. In 2022, nearly 97,000 assisted reproductive technology procedures were conducted in Italy, with IVF cycles accounting for the largest share of activity, reflecting robust clinical throughput and sustained patient demand.
The clinics in the CFA commercial network perform thousands of IVF cycles per annum, providing a substantial potential recurring addressable market for Felix™. CFA will actively engage these clinics to promote and sell Felix™, supporting rapid market penetration and revenue growth beyond initial expectations.
CFA Italia operates within Italy’s large and sophisticated IVF market and maintains established relationships across a broad network of IVF clinics, providing a strong platform for scaled European expansion post-approval. With Italy representing a major global IVF market, this agreement creates a pathway to a substantial recurring addressable market, supporting accelerated adoption and revenue growth as Felix™ is introduced across additional clinics.
Memphasys Non-Executive Director and Chair of Commercialisation, Marjan Mikel said:
“Europe is a core pillar of our global Felix™ commercialisation strategy and this Agreement provides an immediate entry point into the Italian IVF market with a committed supply pathway and clear scalability. With CE Marking expected in early 2026, this momentum positions the Company to accelerate adoption through a well-established clinic network. This Agreement builds on strong operational and commercial progress across the business and we expect to deliver further meaningful milestones in the coming quarters as we continue to execute our growth strategy.”
About us:
About Memphasys
Memphasys Limited (ASX: MEM) is an Australian-based reproductive biotechnology company commercialising the Felix™ System, a patented bio separation technology that isolates the most viable sperm cells for human assisted reproduction.
By combining electrophoresis and size-exclusion membranes, Felix™ delivers a fast, gentle and standardised sperm selection process that enhances sperm quality and reduces laboratory time. The system replaces traditional centrifugation, which can cause cellular stress and DNA damage, offering clinicians a superior, repeatable alternative.
Memphasys’ commercial strategy focuses on building contracted sales through direct and distribution-led channels, scaling production to improve margins, and establishing Felix™ as a new global standard in sperm preparation for ART procedures.
Website: www.memphasys.com
The Felix™ System is a registered trademark of Memphasys Limited. All rights reserved.
Contact details:
David Tasker
Managing Director
Chapter One Advisors
Tel: +61 433 112 936
E: [email protected]
